Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia Van Dam Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto et al. · Journal of Clinical Oncology · 2013
PURPOSE: The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS). PATIENTS AND METHODS: In this phase III study, eligible patients with stage IIIB/IV lung adenocarcinoma were screened for EGFR mutations. Mutation-positive patients were stratified by mutation type (exon 19 deletion, L858R, or other) and race (Asian or non-Asian) before two-to-one random assignment to 40 mg afatinib per day or up to six cycles of cisplatin plus pemetrexed chemotherapy at standard doses every 21 days. The primary end point was PFS by independent review. Secondary end points included tumor response, overall survival, adverse events, and patient-reported outcomes (PROs). RESULTS: A total of 1,269 patients were screened, and 345 were randomly assigned to treatment. Median PFS was 11.1 months for afatinib and 6.9 months for chemotherapy (hazard ratio [HR], 0.58; 95% CI, 0.43 to 0.78; P = .001). Median PFS among those with exon 19 deletions and L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). The most common treatment-related adverse events were diarrhea, rash/acne, and stomatitis for afatinib and nausea, fatigue, and decreased appetite for chemotherapy. PROs favored afatinib, with better control of cough, dyspnea, and pain. CONCLUSION: Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.
Cited by 3,221 works. doi:10.1200/jco.2012.44.2806
Authors
- Lecia Van Dam Sequist
- James Chih‐Hsin Yang
- Nobuyuki Yamamoto
- Kenneth John O'Byrne
- Vera Hirsh
- Tony S.K. Mok
- Sarayut Lucien Geater
- С. В. Орлов
- Chun‐Ming Tsai
- Michael Joseph Boyer
- Wu‐Chou Su
- Jaafar Bennouna
- Terufumi Kato
- В. А. Горбунова
- Ki Hyeong Lee
- Riyaz N.H. Shah
- Dan Massey G
- Victoria Zazulina
- Mehdi Shahidi
- Martin Schüler
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Interpreting the significance of changes in health-related quality-of-life scores.
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain